Nectero Medical is developing the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System, which delivers a proprietary mixture directly to mid-sized abdominal aortic aneurysms to stabilize their growth and reduce the risk of rupture. This treatment aims to minimize the need for major surgical interventions, allowing patients to maintain a normal lifespan without facing the complications associated with traditional endovascular repair or open surgery.
Funding
$123.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NVFounders
Product
Problem
Small to mid-sized abdominal aortic aneurysms (AAA) are typically monitored until they reach a size requiring surgical intervention, but there are currently no treatments to stabilize their growth and reduce the risk of rupture before that point. Current surgical or endovascular treatments are reserved for AAA larger than 5.5cm (5.0cm in women) in diameter, in symptomatic patients, or in rapidly expanding aneurysms. This leaves a gap in treatment options for patients with smaller AAAs.
Solution
Nectero Medical is developing the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System, an investigational treatment designed to stabilize the growth of small to mid-sized AAAs and minimize the risk of rupture. The Nectero EAST® System uses an endovascular approach to deliver a proprietary mixture directly to the site of the aneurysm. By minimizing further degradation of the aneurysm and strengthening the aortic tissue around the aneurysm, the treatment aims to prevent or significantly delay the need for major surgical intervention.
Target Audience
The primary target audience includes patients with small to mid-sized abdominal aortic aneurysms who are not yet candidates for traditional surgical or endovascular repair, as well as vascular surgeons and interventional radiologists.
Features
- Endovascular delivery system for targeted treatment of AAAs.
- Proprietary mixture designed to stabilize aneurysm growth.
- Minimally invasive approach compared to traditional open surgery.
- Potential to delay or prevent the need for major intervention.